Contribuições do 225AC-PSMA no manejo clínico de pacientes com CPMRC

Tatiane Sabriela  Cagol Camozzato; Adaobi  Ejidike; Gerusa Ribeiro; Vagner  Bolzan

doi:10.22481/rsc.v20i2.13399

Autores/as

Tatiane Sabriela Cagol Camozzato Instituto Federal de Santa Catarina, Santa Catarina, Florianópolis. Departamento Academico de Saúde e Serviço, CST Radiologia https://orcid.org/0000-0002-3530-718X
Adaobi Ejidike Instituto Federal de Santa Catarina, Santa Catarina, Florianópolis. Departamento Academico de Saúde e Serviço, CST Radiologia https://orcid.org/0000-0001-7920-2155
Gerusa Ribeiro Instituto Federal de Santa Catarina, Santa Catarina, Florianópolis. Departamento Academico de Saúde e Serviço, CST Radiologia https://orcid.org/0000-0003-3188-8017
Vagner Bolzan Instituto Federal de Santa Catarina, Santa Catarina, Florianópolis. Departamento Academico de Saúde e Serviço, CST Radiologia

DOI:

https://doi.org/10.22481/rsc.v20i2.13399

Palabras clave:

Medicina Nuclear, Metástase Neoplásica, Actínio, Neoplasias da Próstata

Resumen

Esta es una revisión integradora de la literatura, con el objetivo de sistematizar las publicaciones nacionales e internacionales sobre los principales aportes de la Medicina Nuclear en el manejo clínico de los tumores de próstata metastásicos resistentes a la castración, en el uso de la terapia con Ac 225-PSMA. Se investigaron publicaciones científicas indexadas en las bases de datos Pubmed, Cinahl, Scielo, entre 2016 y mayo de 2021, con los siguientes descriptores, medicina nuclear, cáncer de próstata, terapia con radionúclidos, 177LU-PSMA y teranósticos, actinio. El estudio incluyó artículos originales y ensayos teóricos en inglés, español y portugués. Se excluyeron editoriales, artículos de opinión, resúmenes de anales, publicaciones duplicadas, TCC, libros e idiomas que no fueron determinados. La organización y análisis de los artículos fue con la ayuda del software Atlas.ti versión 9.1. Los hallazgos sumaron 153 artículos, luego de aplicar los criterios de inclusión y exclusión se analizaron un total de 9 artículos. A partir de los resultados estos se distribuyeron en categorías siendo, acción terapéutica del 225Ac-PSMA; resultados de estudios clínicos; imagen; y toxicidad y seguridad. Los avances en el abordaje del cáncer de próstata metastásico resistente a la castración con Actin-225 (225Ac-PSMA) pueden garantizar una mejor calidad de vida para los pacientes y un mayor tiempo de respuesta libre de progresión incluso en pacientes rigurosamente pretratados con medicamentos autorizados, o en fase de homologación con 177Lu, ya en uso en el país. La entrega de energía por la emisión alfa de Actinine-225 (225Ac) parece superar la resistencia creada por 177Lu. En conclusión, manejo seguro, alta toxicidad, respuesta y aportes a la supervivencia global y libre de progresión de los pacientes en tratamiento con Actineo-225.

Descargas

Los datos de descargas todavía no están disponibles.

Citas

Instituto Nacional do Câncer (INCA). Estimativa 2020 – Incidência de Câncer no Brasil; 2021 Jun.

Dong, L. et al. Metastatic prostate cancer remains incurable, why? S.I: Asian Sournal of Urology; 2019 Jan. V. 6(1), 26-41 p.

Camozzato, T. et al. Medicina Nuclear na Prática. Florianópolis: Publicações do Ifsc; 2020, 237 p.

Hupe, M.C, et al. A expressão do antígeno de membrana específico da próstata (PSMA) em biópsias é um estratificador de risco independente de pacientes com câncer de próstata no momento do diagnóstico inicial. S.I: Frontiers in Oncology; 2018 Dez. V. 8.

Minners, S. et al. High level PSMA expression is associated with early PSA recurrence in surgically treated prostate cancer. S.I: The Prostate; 2011 Ago. V. 71(3), 281- 288 p.

Sartor, O. et al. Lutetium-177–PSMA-617 for Metastatic Castration-Resistant Prostate Cancer. S.I: New England Journal of Medicine; 2021 Set. V.385(12), 1091-1103 p.

Kratochwil, C. et al. 225Ac-PSMA-617 for therapy of prostate cancer. S.I: Seminars in nuclear medicine; 2020 Mar. V.50(2), 133- 140 p.

Pouget, J. et al. Clinical radioimmunotherapy—the role of radiobiology. S.I: Nature Reviews Clinical oncology; 2011 Nov. V. 8(12), 720-734 p.

Hindié, E. et al. Dose deposits from 90Y, 177Lu, 111In, and 161Tb in micrometastases of various sizes: implications for radiopharmaceutical therapy. S.I: Journal of Nuclear Medicine; 2016 Mai. V. 57(5), 759-764 p.

Sgouros, G. et al. MIRD pamphlet no. 22 (abridged): radiobiology and dosimetry of α-particle emitters for targeted radionuclide therapy. S.I: Journal of nuclear medicine; 2010 Fev. V. 51(2), 311-328 p.

Kratochwil, C. et al. 225Ac-PSMA-617 for PSMA-targeted α-radiation therapy of metastatic castration-resistant prostate cancer. S.I: Journal of Nuclear Medicine; 2016 Dez. V. 57(1)2, 1941-1944 p.

Kassis, A.I. Therapeutic radionuclides: biophysical and radiobiologic principles. SI: Seminars in nuclear medicine; 2008 Set. V. 38(5), 358-366 p.

Kratochwil, C. et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: swimmer-plot analysis suggests efficacy regarding duration of tumor control. S.I: Journal of Nuclear Medicine; 2018 Mai. V. 59(5), 795-802 p.

Sathekge, M, et al. 225Ac-PSMA-617 in chemotherapy-naive patients with advanced prostate cancer: a pilot study. S.I: European journal of nuclear medicine and molecular imaging; 2018 Set. V. 46(1), 129-138 p.

Sathekge, M, et al. Predictors of overall and disease-free survival in metastatic castration-resistant prostate cancer patients receiving 225Ac-PSMA-617 radioligand therapy. S.I: Journal of Nuclear Medicine; 2020 Jan. V. 61(1), 62-69 p.

Yadav, M.P, et al. Efficacy and safety of 225Ac-PSMA-617 targeted alpha therapy in metastatic castration-resistant Prostate Cancer patients. S.I: Theranostics; 2020 Jul. V. 10(2) 9364-9377 p.

Feuerecker, B, et al. Activity and adverse events of actinium-225-PSMA-617 in advanced metastatic castration-resistant prostate cancer after failure of lutetium-177- PSMA. S.I: European Urology; 2021 Mar. V. 79(3), 343-350 p.

Van Der Doelen, M.J, et al. Clinical outcomes and molecular profiling of advanced metastatic castration-resistant prostate cancer patients treated with 225AcPSMA-617 targeted alpha-radiation therapy. S.I: Urologic Oncology: Seminars and Original Investigations; 2021 Out. V.39(10), 729.e7-29.e16 p.

Zacherl, M.J, et al. First Clinical Results for PSMA-Targeted α-Therapy Using 225Ac-PSMA-I&T in Advanced-mCRPC Patients. S.I: Journal of Nuclear Medicine; 2021 Mai. V.62(5), 669-674 p.

Rasheed, R, et al. Alpha therapy with 225Actinium labeled prostate specific membrane antigen: Reporting new photopeak of 78 kilo-electron volts for better image statistics. S.I: Indian Journal of Nuclear Medicine; 2019 Març. V. 34(1), 76-77 p.

Usmani, S, et al. 225Ac prostate-specific membrane antigen posttherapy α imaging: comparing 2 and 3 photopeaks. S.I: Clinical nuclear medicine; 2019 Mai. V. 44(5), 401-403 p.

Vatsa, R, et al. 225Ac-PSMA-617 Radioligand Posttherapy Imaging in Metastatic Castrate-Resistant Prostate Cancer Patient Using 3 Photopeaks. S.I: Clinical nuclear medicine; 2020 Jun. V.45(6), 437-438 p.

Strigari, L, et al. The evidence base for the use of internal dosimetry in the clinical practice of molecular radiotherapy. S.I: European Journal of Nuclear Medicine and Molecular Imaging; 2014 Jun. V41(10), 1976-1988 p.

International Atomic Energy Agency (IAEA) TRS 398. Absorbed Dose Determination in External Beam Radiotherapy: An International Code of Practice for Dosimetry based on Standards of Absorbed Dose to Water. S.I: THE IAEA ON BEHALF OF IAEA; 2006 Jun. V12, 1-83 p.

Chakravarty, R, et al. Targeted α-therapy of prostate cancer using radiolabeled PSMA inhibitors: a game changer in nuclear medicine. S.I: American journal of nuclear medicine and molecular imaging; 2018 Ago. V.8(4), 247-267 p.

Belli, M.L, et al. Targeted Alpha Therapy in mCRPC (Metastatic CastrationResistant Prostate Cancer) Patients: Predictive Dosimetry and Toxicity Modeling of 225Ac-PSMA (Prostate-Specific Membrane Antigen). S.I: Frontiers in Oncology; 2020 Nov. V.10, 1-12 p.

Rathke, H, et al. Initial clinical experience performing sialendoscopy for salivary gland protection in patients undergoing 225Ac-PSMA-617 RLT. S.I: European journal of nuclear medicine and molecular imaging; 2018 Ago. V.46(1), 139-147 p.

Kratochwil, C. et al. Targeted α-therapy of metastatic castration-resistant prostate cancer with 225Ac-PSMA-617: dosimetry estimate and empiric dose finding. S.I: Journal of Nuclear Medicine; 2017 Out. V. 58(10), 1624-1631 p.

Khreish, F, et al. 225Ac-PSMA-617/177Lu-PSMA-617 tandem therapy of metastatic castration-resistant prostate cancer: pilot experience. S.I: European journal of nuclear medicine and molecular imaging; 2019 Nov. V.47(3), 721-728 p.

Hofman, M.S, et al. [177Lu]-PSMA-617 radionuclide treatment in patients with metastatic castration-resistant prostate cancer (LuPSMA trial): a single-centre, single-arm, phase 2 study. S.I: The Lancet Oncology; 2018 Jun. V.19(6), 825-833 p.